Up to now, the first clinical study involving the transplantation of genetically modified cells into human spinal cord, is about amyotrophic lateral sclerosis at 2022, overexpressing glial cell line-derived neurotrophic factor (GDNF) (Baloh et al., 2022). This evidence concerns the gene GDNF and amyotrophic lateral sclerosis.